Search Results

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors MOA: ART0380 selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase CHK1.…

What Black Women Need to Know About Breast Cancer Risk A healthcare provider holding a tablet speaks with a patient seated on an exam table in a medical office Breast cancer is the most commonly diagnosed cancer in Black women. And while Black women have an overall lower breast cancer incidence rate than white women,…

Jody has worked as a nurse practitioner in breast surgical oncology with Maryland Oncology since 2021. She graduated with her Associates of Science degree in nursing in 2006 followed by her BSN in 2008. She completed her undergraduate studies in Pennsylvania and her Masters of Science degree in nursing at George Washington University. The majority…

A PHASE III RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657) MOA: Giredestrant is an oral selective estrogen receptor degrader (SERD) Key Eligibility Criteria: Locally advanced or metastatic…

Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001) MOA: Rinatabart sesutecan (Rina-S) is an FRα-directed antibody drug conjugate with an exatecan payload. Key Eligibility Criteria: Cohort B3 – EGFR-mutated NSCLC Must have received EGFR-targeted therapy and plt-based chemo Part C – High-grade serous PROC 1-3 prior lines…